Low mood and depressive symptoms during perimenopause – Should General Practitioners prescribe hormone replacement therapy or antidepressants as the first-line treatment?
Restricted accessResearch articleFirst published online September, 2019
Low mood and depressive symptoms during perimenopause – Should General Practitioners prescribe hormone replacement therapy or antidepressants as the first-line treatment?
Perimenopausal women have an increased risk of developing new onset and recurrent mental health conditions such as anxiety, low mood and depressive symptoms. General Practitioners frequently prescribe antidepressants as the first-line treatment for these symptoms, despite clear lack of evidence for their efficacy and their unfavourable side effect profile. This article, written by a General Practitioner, gives a practical overview of the mental health symptoms which women may report to their General Practitioners during the menopausal transition and discusses underlying causes, assessment, risk factors and treatment options based on current evidence.
HillardTAbernethyKHamodaH, et al. Management of the menopause. 6th ed.
UK:
British Menopause Society, 2017, p.2.
2.
McKinlaySMBrambillaDJPosnerJ.The normal menopause transition.Maturitas1992;
14: 103–115.
3.
SchmidtPJRubinowDR.Sex hormones and mood in the perimenopause.Ann N Y Acad Sci2009;
1179: 70–85.
4.
CohenLSSoaresCNVitonisAF, et al.
Risk for new onset of depression during the menopausal transition: the Harvard study of moods and cycles.Arch Gen Psychiatry2006;
63: 385–390.
PayneJLTeitelbaum-PalmerJJoffeH.A reproductive subtype of depression: conceptualizing models and moving toward etiology.Harv Rev Psychiatry2009;
17: 72–86.
7.
NappiRETonaniSSantamariaV, et al.Luteal phase dysphoric disorder and premenstrual syndrome. Ital J Psych2009;
28: 27–33.
8.
GordonJLRubinowDREisenlohr-MoulTA, et al.
Efficacy of transdermal estradiol and micronized progesterone in the prevention of depressive symptoms in the menopause transition: a randomized clinical trial. JAMA Psychiatry2018;
75: 149–157.
9.
SoaresCNAlmeidaOPJoffeH, et al.
Efficacy of estradiol for the treatment of depressive disorders in perimenopausal women: a double-blind, randomized, placebo-controlled trial.Arch Gen Psychiatry2001;
58: 529–534.
10.
SchmidtPJNiemanLDanaceauMA, et al.
Estrogen replacement in perimenopause-related depression: a preliminary report.Am J Obstet Gynecol2000;
183: 414–420.
NICE. Menopause: diagnosis and management.
UK:
NICE, 2015.
13.
Writing Group for the Women’s Health Initiative Investigators.
Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the women’s health initiative randomized controlled Trial. JAMA2002;
288: 321–333.
14.
McIntyreRSKonrskiJZGrigoriadisS, et al.
Hormone replacement therapy and antidepressant prescription patterns: a reciprocal relationship.CMAJ2005;
4: 172.
15.
MakiPKornsteinSGHadineJ, et al.
Guidelines for the evaluation and treatment of perimenopausal depression: summary and recommendations.Menopause2018;
25: 1069–1085.
16.
ToffolEHeikinheimoOPartonenT.Hormone therapy and mood in perimenopausal and postmenopausal women: a narrative review.Menopause2015;
22: 564–578.
17.
ParryBL.Optimal management of perimenopausal depression.Int J Womens Health2010;
2: 143–151.
18.
SoaresCNFreyBN.Challenges and opportunities to manage depression during the menopausal transition and beyond.Psychiatr Clin N Am2010;
33: 295–308.
19.
KulkarniJGavrilidisEHudaibAR, et al.
Development and validation of a new rating scale for perimenopausal depression – the Meno-D. Transl Psychiatry2018;
8: 123–131.
20.
WhartonWGleasonCEOlsonSR, et al.
Neurobiological underpinnings of estrogen-mood relationship.Curr Psychiatry Rev2012;
8: 247–256.
21.
SchmidtPJBenDRMartinezPE, et al.
Effects of estradiol withdrawal on mood in women with past perimenopausal depression: a randomized clinical trial. JAMA Psychiatry2015;
72: 714–726.
22.
GordonJLRubinowDREisenlohr-MoulTA, et al.
Estradiol variability, stressful life events and the emergence of depressive symptomatology during menopause transition.Menopause2016;
23: 257–266.
23.
GordonJLEisenlohr-MoulTARubinowDR, et al.
Naturally occurring changes in estradiol concentrations in the menopause transition predict morning cortisol and negative mood in perimenopausal depression.Clin Psychol Sci2016;
4: 919–935.
24.
GuptaSMukherjeeABiswasS, et al.
Evaluation of endocrine parameters as predictor of major depressive disorder.Indian J Psychol Med2017;
39: 766–769.
25.
FreemanEWSammelMD, et al.
Premenstrual syndrome as a predictor of menopausal symptoms.Obstet Gynecol2004;
103: 960–966.
26.
BrombergerJTKravitzHM.Mood and menopause: findings from the study of women’s health across the nation (SWAN) over 10 years.Obstet Gynecol Clin North Am2011;
38: 609–625.
27.
HillardTAbernethyKHamodaH, et al. Management of the menopause. 6th ed.
UK:
British Menopause Society, 2017, p.36.
28.
GreeneJ.A factor analytic study of climacteric symptoms.J Psychosom Res1976;
20: 425–430.
29.
GreenSMKeyBLMcCabeRE.Cognitive-behavioural, behavioural, and mindfulness-based therapies for menopausal depression: a review.Maturitas2015;
80: 37–47.
30.
GrazziottinASerafiniA.Depression and the menopause: why antidepressants are not enough?Menopause Int2009;
15: 76–81.
31.
WorsleyRDavisSRGavrilidisE, et al.
Hormonal therapies for new onset and relapsed depression during perimenopause.Maturitas2012;
73: 127–133.
32.
NewsonLR.Best practice for HRT: unpicking the evidence.Br J Gen Pract2016;
66: 597–598.
33.
HillardTAbernethyKHamodaH, et al. Management of the menopause. 6th ed.
UK:
British Menopause Society, 2017, p.121.
34.
NewsonL.Menopause and cardiovascular disease.Post Reprod Health2018;
24: 44–49.
35.
SoaresCNZitekB.Reproductive hormone sensitivity and risk for depression across the female life cycle: a continuum of vulnerability?J Psychiatry Neurosci2008;
33: 331–343.
36.
PanayNStuddJ.Progestogen intolerance and compliance with hormone replacement therapy in menopausal women.Hum Reprod Update1997;
3: 159–171.
37.
CiprianiAFurukawaTASalantiG, et al.
Comparative efficacy and acceptability of 21 antidepressant drugs for the acute treatment of adults with major depressive disorder: a systematic review and network meta-analysis.Lancet2018;
391: 1357–1366.
38.
ClaytonAHKornsteinSGDunlopBW, et al.
Efficacy and safety of desvenlafaxine 50 mg/d in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.J Clin Psychiatry2013;
74: 1010–1017.
39.
KornsteinSGJiangQReddyS, et al.
Shortterm efficacy and safety of desvenlafaxine in a randomized, placebo-controlled study of perimenopausal and postmenopausal women with major depressive disorder.J Clin Psychiatry2010;
71: 1088–1096.
40.
HickeyMSzaboRAHunterM,
Non-hormonal treatments for menopausal symptoms. BMJ2017;
23: 359–366.
41.
StubbsCMattinglyLCrawfordSA, et al.
Do SSRIs and SNRIs reduce the frequency and/or severity of hot flashes in menopausal women.J Okla State Med Assoc2017;
110: 272–274.
42.
Tan O, Pinto A and Carr BR. Hormonal and non-hormonal management of vasomotor symptoms: a narrated review. J Endocrinol Diabetes Obes 2013; 1: 1009–1024.
43.
RonaldJLiLKimMJ, et al.
FDA approval of paroxetine for menopausal hot flushes.N Engl J Med2014;
370: 1777–1779.
44.
SheuYi-hanLanteigneAStürmerT, et al.
SSRI use and risk of fractures among perimenopausal women without mental disorders.Inj Prev2015;
21: 397–403.
45.
AndrewsPWThomsonJAAmstadterA, et al.
Primum non nocere: an evolutionary analysis of whether antidepressants do more harm than good. Front Psychol2012;
3: 117–136.
46.
KimDJoffeH.Use of antidepressants during perimenopause.Womens Health2006;
2: 627–637.
47.
American Psychiatric Association. Diagnostic and statistical manual of mental disorders. 5th ed.
Arlington, VA:
American Psychiatric Association, 2013.
48.
BrombergerJTKravitzHMChangYF, et al.
Major depression during and after the menopausal transition: study of women’s health across the nation (SWAN). Psychol Med2011;
41: 1879–1888.
